The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Abstract
MDM2 binds the p53 tumor suppressor protein with high affinity and negatively modulates its transcriptional activity and stability. Overexpression of MDM2, found in many human tumors, effectively impairs p53 function. Inhibition of MDM2-p53 interaction can stabilize p53 and may offer a novel strategy for cancer therapy. Here, we identify potent and selective small-molecule antagonists of MDM2 and confirm their mode of action through the crystal structures of complexes. These compounds bind MDM2 in the p53-binding pocket and activate the p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and growth inhibition of human tumor xenografts in nude mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“WB138 increases the levels of both p53 and MDM2, which is consistent with the activity of previous reports on MDM2 inhibitors[28,32–36].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [32]
In the citing paper
“Nutlin-3a had the strongest activity, and its binding activity with MDM2 reached 90 nM.”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [20]
In the citing paper
“At 200 mg/kg, twice a day, 20 days after oral administration of Nutlin-3a, the tumor growth inhibition rate reached 90%, with no obvious side effects [20].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [20]
In the citing paper
“Moreover, others have shown that inhibition of MDM2 binding to p53 or p73α appears to be more effective at promoting p53- and p73α-mediated apoptosis in cancer cells compared with normal cells.19,45”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [45]
In the citing paper
“Nutlin-3a is a small molecule, which binds to the N-terminal hydrophobic pocket of Mdm2 and blocks protein-protein interactions (PPIs) between Mdm2 and p53 (10).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [10]
In the citing paper
“It has been reported that a consequence of Nutlin treatment is elevated Mdm2 protein levels, and this occurs in cells with or without p53 (6,8).”
From Pharmacologically increasing Mdm2 Inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells (2015) · cites this paper as [6]
In the citing paper
“Nutlin-3 is a small molecule inhibitor of Mdm2/p53 interaction that can induce apoptosis in cancer cells through activation of p53.”
From Pharmacologically increasing Mdm2 Inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells (2015) · cites this paper as [6]
In the citing paper
“Nonmalignant tissues tolerate inhibition of Mdm2, and no overt toxicity was observed in preclinical in vivo models.9,11”
From Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death (2013) · cites this paper as [9]
In the citing paper
“For example, small molecule antagonism of the Mdm2–p53 interaction promotes p53-dependent tumor regression in murine models [102,103].”
From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [103]
In the citing paper
“Small-molecule PPI antagonists that disrupt the p53–MDM2 interaction have been identified, including nutlin 3a96 and MI-219 (Ref. 97).”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [96]
In the citing paper
“To utilize MDM2 for the PROTAC system, the discovery of nutlins, small molecules that bind MDM2 at the p53 interaction interface, was a crucial step [66].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [66]
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,474
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Research works printed but not linked: 3
- D. Freedman, A. J. Levine, Cell. Mol. Life Sci.5, 96 (1999).
- R. Zhang, H. Wang, Methods Mol. Med.85, 205 (2003).
- L. T. Vassilevet al., Anticancer Drug Des.13, 359 (2001).
Cited by
Sorted by citations
Items 701–800 of 1,103
Sharma, M. D., Rodrı́guez, P. C., Koehn, B. H., Baban, B., Cui, Y. R., Guo, G., Shimoda, M., Pacholczyk, R., Shi, H., Lee, E.-J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.014 · Cited by 121
p53: emerging roles in stem cells, development and beyond
Jain, A. K., & Barton, M. C. (2018) · Development · doi:10.1242/dev.158360 · Cited by 130
Strategies for designing proteolysis targeting chimaeras (PROTACs)
He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C. (2022) · Medicinal Research Reviews · doi:10.1002/med.21877 · Cited by 120
Spotlight on the role of COP1 in tumorigenesis
Marine, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3271 · Cited by 120
Sammons, M. A., Zhu, J., Drake, A. M., & Berger, S. L. (2014) · Genome Research · doi:10.1101/gr.181883.114 · Cited by 117
Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation
Wang, Y. V., Wade, M., Wong, E., Li, Y.-C., Rodewald, L. W., & Wahl, G. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701497104 · Cited by 116
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Yuan, Y., Liao, Y.-M., Hsueh, C.-T., & Mirshahidi, H. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-16 · Cited by 120
Senotherapeutic drugs for human intervertebral disc degeneration and low back pain
Cherif, H., Bisson, D. G., Mannarino, M., Rabau, O., Ouellet, J. A., & Haglund, L. (2020) · eLife · doi:10.7554/elife.54693 · Cited by 119
KRAB-type zinc-finger protein Apak specifically regulates p53-dependent apoptosis
Tian, C., Xing, G., Xie, P., Lu, K., Nie, J., Wang, J., Li, L., Gao, M., Zhang, L., & He, F. (2009) · Nature Cell Biology · doi:10.1038/ncb1864 · Cited by 120
Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis
Grinkevich, V. V., Nikulenkov, F., Shi, Y., Enge, M., Bao, W., Malyukova, A., Gluch, A., Kel, A. E., Sangfelt, O., & Selivanova, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.021 · Cited by 118
Targeting protein–protein interactions, a wide open field for drug design
Bakail, M., & Ochsenbein, F. (2016) · Comptes Rendus. Chimie · doi:10.1016/j.crci.2015.12.004 · Cited by 117
TSPYL5 suppresses p53 levels and function by physical interaction with USP7.
Epping, M. T., Meijer, L. A. T., Krijgsman, O., Bos, J. L., Pandolfi, P. P., & Bernards, R. (2011) · Nature Cell Biology · doi:10.1038/ncb2142 · Cited by 117
A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0581 · Cited by 117
Mechanisms of regulatory diversity within the p53 transcriptional network
Espinosa, J. M. (2008) · Oncogene · doi:10.1038/onc.2008.37 · Cited by 115
p53-dependent repression of polo-like kinase-1 (PLK1)
McKenzie, L., King, S., Marcar, L., Nicol, S., Dias, S. S., Schumm, K., Robertson, P., Bourdon, J., Perkins, N. D., Fuller-Pace, F. V., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13532 · Cited by 120
Human protein–protein interaction networks and the value for drug discovery
Ruffner, H., Bauer, A., & Bouwmeester, T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.011 · Cited by 118
Pal, S., Bhattacharjee, A., Ali, A., Mandal, N. C., Mandal, S. C., & Pal, M. (2014) · Journal of Inflammation · doi:10.1186/1476-9255-11-23 · Cited by 119
p53: Twenty five years understanding the mechanism of genome protection
Gómez-Lázaro, M., Fernández-Gómez, F.-J., & Jordán, J. (2004) · Journal of Physiology and Biochemistry · doi:10.1007/bf03167075 · Cited by 119
Hu, W., Feng, Z., Modica, I., Klimstra, D. S., Song, L., Allen, P. J., Brennan, M. F., Levine, A. J., & Tang, L. H. (2010) · Genes & Cancer · doi:10.1177/1947601910371979 · Cited by 115
Bacteria-host relationship: ubiquitin ligases as weapons of invasion
Maculins, T., Fiškin, E., Bhogaraju, S., & Đikić, I. (2016) · Cell Research · doi:10.1038/cr.2016.30 · Cited by 121
Advances and challenges in targeting IRF5, a key regulator of inflammation
Almuttaqi, H., & Udalova, I. A. (2018) · FEBS Journal · doi:10.1111/febs.14654 · Cited by 116
The role of TP53 in acute myeloid leukemia: Challenges and opportunities
Barbosa, K., Li, S., Adams, P. D., & Deshpande, A. J. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22796 · Cited by 118
Post-translational control of beige fat biogenesis by PRDM16 stabilization
Wang, Q., Li, H., Tajima, K., Verkerke, A. R. P., Taxin, Z. H., Hou, Z.-S., Cole, J. B., Li, F., Wong, J., Abe, I., et al. (2022) · Nature · doi:10.1038/s41586-022-05067-4 · Cited by 121
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
Ré, D., Thomas, R. K., Behringer, K., & Diehl, V. (2005) · Blood · doi:10.1182/blood-2004-12-4750 · Cited by 116
Binding Induced Folding in p53−MDM2 Complex
Chen, H., & Luo, R. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0678774 · Cited by 116
Screening for peptide drugs from the natural repertoire of biodiverse protein folds
Watt, P. M. (2006) · Nature Biotechnology · doi:10.1038/nbt1190 · Cited by 116
Ito, M., Barys, L., O'Reilly, T., Young, S., Gorbatcheva, B., Monahan, J., Zumstein-Mecker, S., Choong, P. F., Dickinson, I., Crowe, P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2050 · Cited by 115
A Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction
Liu, M., Pazgier, M., Li, C., Yuan, W., Li, C., & Lu, W. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201000329 · Cited by 115
Srinivasan, P., Yasgar, A., Luci, D. K., Beatty, W. L., Hu, X., Andersen, J. F., Narum, D. L., Moch, J. K., Sun, H., Haynes, J. D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3261 · Cited by 115
Regulation of p53 is critical for vertebrate limb regeneration
Yun, M. H., Gates, P. B., & Brockes, J. P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310519110 · Cited by 116
Pettersen, E. O., Ebbesen, P., Gieling, R. G., Williams, K. J., Dubois, L. J., Lambin, P., Ward, C., Meehan, J., Kunkler, I. H., Langdon, S. P., et al. (2014) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2014.966704 · Cited by 116
Cellular senescence: a promising strategy for cancer therapy
Lee, S., & Lee, J. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.294 · Cited by 117
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H. W., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 122
Lu, Y., Nikolovska‐Coleska, Z., Fang, X., Gao, W., Shangary, S. K., Qiu, S., Qin, D., & Wang, S. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060023+ · Cited by 116
p53—A Natural Cancer Killer: Structural Insights and Therapeutic Concepts
Römer, L., Klein, C., Dehner, A., Kessler, H., & Büchner, J. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600611 · Cited by 117
Self-citationIntrinsically disordered proteins and novel strategies for drug discovery
Uversky, V. N. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.686489 · Cited by 120
Pathologies Associated with the p53 ResponsePreprint
Gudkov, A. V., & Komarova, E. A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001180 · Cited by 119
Vilgelm, A. E., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., Weller, K. P., Horton, L. W., McClain, C. M., Ayers, G. D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2405 · Cited by 115
p53 induces transcriptional and translational programs to suppress cell proliferation and growth
Loayza-Puch, F., Drost, J., Rooijers, K., Lopes, R., Elkon, R., & Agami, R. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r32 · Cited by 114
Manfé, V., Biskup, E., Rosbjerg, A., Kamstrup, M. R., Skov, A. G., Lerche, C. M., Lauenborg, B. T., Ødum, N., & Gniadecki, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029541 · Cited by 114
Kojima, K., Shimanuki, M., Shikami, M., Samudio, I. J., Ruvolo, V. R., Corn, P. G., Hanaoka, N., Konopleva, M. Y., Andreeff, M., & Nakakuma, H. (2008) · Leukemia · doi:10.1038/leu.2008.158 · Cited by 115
De, C. K., & Seidel, D. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2060462 · Cited by 114
Survey of the year 2004 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.753 · Cited by 117
Wu, X., He, C., Wu, Y., Chen, X., & Cheng, J. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201502742 · Cited by 113
Goh, W. L., Lee, M. Y., Joseph, T. L., Quah, S. T., Brown, C. J., Verma, C. S., Brenner, S., Ghadessy, F. J., & Teo, Y. N. (2014) · Journal of the American Chemical Society · doi:10.1021/ja413031h · Cited by 114
Optical Biosensors Based on Photonic Crystals Supporting Bound States in the Continuum
Romano, S., Lamberti, A., Masullo, M., Penzo, E., Cabrini, S., Rendina, I., & Mocella, V. (2018) · Materials · doi:10.3390/ma11040526 · Cited by 113
The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise
Mandinova, A., & Lee, S. W. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001366 · Cited by 116
Molchadsky, A., Ezra, O., Amendola, P. G., Krantz, D., Kogan-Sakin, I., Buganim, Y., Rivlin, N., Goldfinger, N., Folgiero, V., Falcioni, R., et al. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.9 · Cited by 117
Riedinger, C., Endicott, J., Kemp, S. J., Smyth, L. A., Watson, A. F., Valeur, E., Golding, B. T., Griffin, R. J., Hardcastle, I. R., Noble, M. E. M., et al. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8062088 · Cited by 113
p53 and its downstream proteins as molecular targets of cancer
Sun, Y. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20231 · Cited by 112
Six1: A critical transcription factor in tumorigenesis
Wu, W., Ren, Z., Li, P., Yu, D., Chen, J., Huang, R., & Liu, H. (2014) · International Journal of Cancer · doi:10.1002/ijc.28755 · Cited by 112
Targeting nucleocytoplasmic transport in cancer therapy
Hill, R., Cautain, B., de Pedro, N., & Link, W. (2013) · Oncotarget · doi:10.18632/oncotarget.1457 · Cited by 117
Targeting p53 by small molecules in hematological malignancies
Saha, M. N., Qiu, L., & Chang, H. H. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-23 · Cited by 112
Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm
Tsafou, K., Tiwari, P. B., Forman-Kay, J. D., Metallo, S. J., & Toretsky, J. A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.04.008 · Cited by 113
p53 mediates target gene association with nuclear speckles for amplified RNA expression
Alexander, K. A., Coté, A., Nguyen, S. C., Zhang, L., Gholamalamdari, O., Agudelo-Garcia, P. A., Lin-Shiao, E., Tanim, K. M. A. A., Lim, J., Biddle, N., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.006 · Cited by 112
Gu, L., Zhu, N., Findley, H. W., & Zhou, M. L. (2008) · Leukemia · doi:10.1038/leu.2008.11 · Cited by 112
Targeting the Checkpoint to Kill Cancer Cells
Benada, J., & Macůrek, L. (2015) · Biomolecules · doi:10.3390/biom5031912 · Cited by 115
Patrick, A. N., Cabrera, J. H., Smith, A. L., Chen, X. S., Ford, H. L., & Zhao, R. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2505 · Cited by 111
Robertson, N., & Spring, D. R. (2018) · Molecules · doi:10.3390/molecules23040959 · Cited by 116
Leu, J. I.-J., Murphy, M. E., & George, D. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821277116 · Cited by 113
Kassab, A. E., Gedawy, E. M., Hamed, M. I. A., Doghish, A. S., & Hassan, R. A. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1901089 · Cited by 112
Connor, C. J. O., Laraia, L., & Spring, D. R. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15053g · Cited by 111
Das, M., Duan, W., & Sahoo, S. K. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.09.002 · Cited by 112
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Laroche-Clary, A., Chaire, V., Algeo, M.-P., Derieppe, M.-A., Loarer, F. L., & Italiano, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0482-3 · Cited by 111
The aggregation of mutant p53 produces prion-like properties in cancer
Rangel, L. P., da Costa, D. C. F., Vieira, T. C. R. G., & Silva, J. L. (2014) · Prion · doi:10.4161/pri.27776 · Cited by 111
DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation
Uxa, S., Bernhart, S. H., Mages, C. F., Fischer, M., Kohler, R., Hoffmann, S., Stadler, P. F., Engeland, K., & Müller, G. A. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz635 · Cited by 121
Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope
Zafar, A., Wang, W., Liu, G., Xian, W., McKeon, F., Zhou, J., & Zhang, R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.023 · Cited by 108
The SIX1-EYA transcriptional complex as a therapeutic target in cancer
Blevins, M. A., Towers, C. G., Patrick, A. N., Zhao, R., & Ford, H. L. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.978860 · Cited by 106
Zhang, Q., Zeng, S. X., Zhang, Y., Zhang, Y.-W., Ding, D., Ye, Q.-Z., Meroueh, S. O., & Lu, H. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100211 · Cited by 110
Viral Oncogene–Induced DNA Damage Response Is Activated in Kaposi Sarcoma Tumorigenesis
Koopal, S., Furuhjelm, J., Järviluoma, A., Jäämaa, S., Pyakurel, P., Pussinen, C., Wirzenius, M., Biberfeld, P., Alitalo, K. K., Laiho, M., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030140 · Cited by 112
Intrinsically Disordered Proteins: From Sequence and Conformational Properties toward Drug Discovery
Rezaei‐Ghaleh, N., Blackledge, M. J., & Zweckstetter, M. (2012) · ChemBioChem · doi:10.1002/cbic.201200093 · Cited by 113
Coffin, A. B., Rubel, E. W., & Raible, D. W. (2013) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-013-0404-1 · Cited by 112
The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation
Aylon, Y., Gershoni, A., Rotkopf, R., Biton, I. E., Porat, Z., Koh, A. P., Sun, X., Lee, Y., Fiel, M.-I., Hoshida, Y., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)61580-0 · Cited by 105
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
Sincere, N. I., Anand, K., Ashique, S., Yang, J., & You, C. (2023) · Molecules · doi:10.3390/molecules28104014 · Cited by 112
Brighenti, E., Calabrese, C., Liguori, G., Giannone, F. A., Treré, D., Montanaro, L., & Derenzini, M. (2014) · Oncogene · doi:10.1038/onc.2014.1 · Cited by 111
Anti-Apoptosis Mechanisms in Malignant Gliomas
Ziegler, D. S., Kung, A. L., & Kieran, M. W. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9717 · Cited by 110
Autophagy promotes mammalian survival by suppressing oxidative stress and p53
Yang, Y., Karsli-Uzunbas, G., Poillet-Perez, L., Sawant, A., Hu, Z. S., Zhao, Y., Moore, D., Hu, W., & White, E. (2020) · Genes & Development · doi:10.1101/gad.335570.119 · Cited by 100
Targeting Protein–Protein Interactions and Fragment-Based Drug Discovery
Valkov, E., Sharpe, T., Marsh, M., Greive, S., & Hyvönen, M. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_265 · Cited by 107
Targeting tumor suppressor genes for cancer therapy
Liu, Y., Hu, X., Han, C., Wang, L., Zhang, X., He, X., & Lu, X. (2015) · BioEssays · doi:10.1002/bies.201500093 · Cited by 112
Jin, F., Chen, Y., Lai, L., & Liu, Z. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003249 · Cited by 108
MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification
Kwon, D., Eom, G. H., Ko, J. H., Shin, S., Joung, H., Choe, N., Nam, Y. S., Min, H.-K., Kook, T., Yoon, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms10492 · Cited by 107
Human fetal brain self-organizes into long-term expanding organoids
Hendriks, D. F. G., Pagliaro, A., Andreatta, F., Ma, Z., van Giessen, J., Massalini, S., López‐Iglesias, C., van Son, G. J. F., DeMartino, J., Damen, M. J. A., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.012 · Cited by 108
Gannon, H. S., Woda, B. A., & Jones, S. N. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.011 · Cited by 105
Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities
Landré, V., Rotblat, B., Melino, S., Bernassola, F., & Melino, G. (2014) · Oncotarget · doi:10.18632/oncotarget.2431 · Cited by 108
Multiscale Ensemble Modeling of Intrinsically Disordered Proteins: p53 N-Terminal Domain
Terakawa, T., & Takada, S. (2011) · Biophysical Journal · doi:10.1016/j.bpj.2011.08.003 · Cited by 105
Nichols, C. A., Gibson, W. J., Brown, M. S., Kosmicki, J. A., Busanovich, J. P., Wei, H. Y., Urbanski, L. M., Currimjee, N., Berger, A. C., Gao, G. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16399-y · Cited by 107
p53 and MDM2 in renal cell carcinoma
Noon, A. P., Vlatković, N., Polański, R., Maguire, M., Shawki, H., PARSONS, K. F., & Boyd, M. T. (2010) · Cancer · doi:10.1002/cncr.24841 · Cited by 109
Anders, C., Higuchi, Y., Koschinsky, K., Bartel, M., Schumacher, B., Thiel, P., Nitta, H., Preisig-Müller, R., Schlichthörl, G., Renigunta, V., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.015 · Cited by 106
DNA damage strength modulates a bimodal switch of p53 dynamics for cell-fate control
Chen, X., Chen, J., Gan, S., Guan, H., Zhou, Y., Ouyang, Q., & Shi, J. (2013) · BMC Biology · doi:10.1186/1741-7007-11-73 · Cited by 109
Bill, K. L. J., Garnett, J., Meaux, I., Ma, X., Creighton, C. J., Bolshakov, S. V., Barrière, C., Debüssche, L., Lazar, A. J., Prudner, B. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1522 · Cited by 108
Targeting prostate cancer based on signal transduction and cell cycle pathways
Lee, J. T., Lehmann, B. D., Terrian, D. M., Chappell, W. H., Stivala, F., Libra, M., Martelli, A. M., Steelman, L. S., & McCubrey, J. A. (2008) · Cell Cycle · doi:10.4161/cc.7.12.6166 · Cited by 104
The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells
Johannessen, T.-C. A., Prestegarden, L., Grudic, A., Hegi, M. E., Tysnes, B. B., & Bjerkvig, R. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos301 · Cited by 103
Suppression of Host p53 Is Critical for Plasmodium Liver-Stage Infection
Kaushansky, A., Ye, A. S., Austin, L. S., Mikolajczak, S. A., Vaughan, A. M., Camargo, N. M., Metzger, P. G., Douglass, A. N., MacBeath, G., & Kappe, S. H. I. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.02.010 · Cited by 105
Meyer, K. D., Donner, A. J., Knuesel, M. T., York, A. G., Espinosa, J. M., & Taatjes, D. J. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.78 · Cited by 109
Kim, H., Nguyen, Y., Yen, C. P., Chagal, L., Lough, A. J., Kim, B. M., & Chin, J. (2008) · Journal of the American Chemical Society · doi:10.1021/ja803951u · Cited by 105
Kojima, K., McQueen, T. J., Chen, Y., Jacamo, R. O., Konopleva, M. Y., Shinojima, N., Shpall, E. J., Huang, X., & Andreeff, M. (2011) · Blood · doi:10.1182/blood-2011-02-334136 · Cited by 108
Driehuis, E., Spelier, S., Hernández, I. B., de Bree, R., Willems, S. M., Clevers, H. C., & Oliveira, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111880 · Cited by 108
Retinoblastoma Tumor Suppressor: Where Cancer Meets the Cell Cycle
Knudsen, E. S., & Knudsen, K. E. (2006) · Experimental Biology and Medicine · doi:10.1177/153537020623100713 · Cited by 106
Restoration of p53 to limit tumor growth
Wang, W., & El‐Deiry, W. S. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f31d6f · Cited by 105
Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation
Weber, A., Marquardt, J., Elzi, D. J., Forster, N., Starke, S., Glaum, A., Yamada, D., Defossez, P., Delrow, J. J., Eisenman, R. N., et al. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.85 · Cited by 104
Metadata
- Authors
- Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., & Liu, E. A.
- Affiliations
- Department of Discovery Oncology, Roche Research Center, Hoffmann–La Roche, Inc., Nutley, NJ 07110, USA.
- Corresponding author
- Vassilev, Lyubomir T.
- Venue
- Science
- Published
- 2004-02-06
- Volume
- 303
- Issue
- 5659
- Pages
- 844-848
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2097933346
- Cited by
- 4,661
- References
- 21
- Citations by year
- 2026: 119 · 2025: 166 · 2024: 169 · 2023: 203 · 2022: 204 · 2021: 199 · 2020: 226 · 2019: 212 · 2018: 216 · 2017: 209 · 2016: 258 · 2015: 248 · 2014: 296 · 2013: 273 · 2012: 265
- FWCI
- 83.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- MDM2, p53, small molecule antagonists, p53 stabilization, p53-MDM2 interaction, cancer therapy, cell cycle arrest, apoptosis, tumor xenografts, crystal structure
- MeSH terms
- Animals, Binding Sites, Cell Cycle, Cell Division, Cell Line, Cell Survival, Crystallization, Dose-Response Relationship, Drug, Humans, Imidazoles, Mice, Nude, Models, Molecular, Molecular Weight, Neoplasm Transplantation, Neoplasms, Experimental, Nuclear Proteins, Phosphorylation, Piperazines, Protein Conformation, Proto-Oncogene Proteins, Stereoisomerism, Transplantation, Heterologous, Gene Expression, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Crystallography, X-Ray, NIH 3T3 Cells, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p21, Mice, Proto-Oncogene Proteins c-mdm2, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
